2022 and Pharma - Pharma Rep Focus

Editor's corner: Fierce Pharma's top 10 stories of 2022

Fierce Pharma

DECEMBER 21, 2022

Editor's corner: Fierce Pharma's top 10 stories of 2022. Wed, 12/21/2022 - 08:42. esagonowsky.

Pharma

Roche Expands Its Scope in Allogeneic Cell Therapy With $1B Poseida Therapeutics Acquisition

MedCity News

NOVEMBER 26, 2024

The two companies have been partners in hematological malignancies since 2022. Roche is acquiring Poseida Therapeutics, a biotech developing allogeneic cell therapies for cancers and immunological indications.

Biopharma

Biopharma Pharma

Drug Approvals in 2022: A Recap of Notable FDA Regulatory Decisions

MedCity News

JANUARY 5, 2023

Fewer new drugs won FDA approvals in 2022 compared to previous years, but some of the products that passed regulatory muster are indicative of trends expected to continue into 2023. For example, more gene and cell therapies are on track to face regulatory decisions in the coming year.

FDA

FDA Biopharma Pharma

Bristol Myers Squibb’s Sotyktu Meets Goals in Two Pivotal Psoriatic Arthritis Studies

MedCity News

DECEMBER 23, 2024

Sotyktu, which became the first TYK2 inhibitor to reach the market after its 2022 FDA approval in plaque psoriasis, now has positive data from two pivotal tests in psoriatic arthritis. Bristol Myers Squibb is trying to add new indications for the drug and stay ahead of competitors including Takeda Pharmaceutical.

FDA

FDA Pharmaceutical Marketing Biopharma

A realistic view of healthcare in 2022

World of DTC Marketing

JANUARY 1, 2022

3hree: Pharma will increase its spending in digital, but a lot of the money will be wasted. Studies show that tens of millions of dollars are being wasted due to fraud with programmatic advertising, but many pharma companies are still wasting money on the channel. The post A realistic view of healthcare in 2022.

Healthcare

Healthcare Healthcare Side effects Prescription

10 noteworthy pharma leadership shake-ups this year

PharmaVoice

DECEMBER 7, 2022

From GSK to Roche to Biogen, these were the most impactful executive changes at leading pharma companies in 2022.

Pharma

Pharma Leads

Activist shareholders ask 9 big pharmas to consider whether 'excessive' patenting hurts access

Fierce Pharma

DECEMBER 15, 2022

Activist shareholders ask 9 big pharmas to consider whether 'excessive' patenting hurts access. Thu, 12/15/2022 - 10:51.

Pharma

Pharma Injecting Life into Digital Health Amidst Funding Downturn

MedCity News

JUNE 16, 2023

The consensus is 2022 was a challenging year for digital health companies. billion in 2022 — down 56% from $40.2 billion in 2022 — down 56% from $40.2 Rather, 2022 represents an overdue correction in the midst of global economic uncertainty after a period of overexuberance and lofty expectations in digital health.

Pharma

Pharma Food and Drug Administration Recruitment Patients

2023 forecast: FDA revamps cancer drug approvals, and Big Pharma is willing to fall in line

Fierce Pharma

DECEMBER 18, 2022

2023 forecast: FDA revamps cancer drug approvals, and Big Pharma is willing to fall in line. Sun, 12/18/2022 - 17:18.

Pharma

Pharma FDA

How pharma marketing must adapt to patient personalization

Fierce Pharma

NOVEMBER 10, 2022

How pharma marketing must adapt to patient personalization. Thu, 11/10/2022 - 18:32.

Marketing

Marketing Pharma Patients

Thea Pharma gets FDA nod for preservative-free rival to Sun and Viatris glaucoma eye drops

Fierce Pharma

DECEMBER 20, 2022

Thea Pharma gets FDA nod for preservative-free rival to Sun and Viatris glaucoma eye drops. Tue, 12/20/2022 - 04:53.

Pharma

Pharma FDA

AbbVie CEO Gonzalez scored $26M in 2022 pay as cash cow Humira neared patent cliff

Fierce Pharma

MARCH 7, 2023

AbbVie CEO Gonzalez scored $26M in 2022 pay as cash cow Humira neared patent cliff aliu Tue, 03/07/2023 - 10:54

Cancer Biotech Repare Therapeutics Restructures to Focus on Clinical-Stage Pipeline

MedCity News

AUGUST 29, 2024

The most advanced program is camonsertib, whose rights Repare recently regained from Roche after the pharma giant terminated an alliance started in 2022. Repare Therapeutics is cutting discovery and preclinical work to focus on its clinical-stage cancer drugs.

Pharma

Pharma Biopharma

In another leadership change at Roche, Anderson departs as pharma CEO

Fierce Pharma

DECEMBER 12, 2022

In another leadership change at Roche, Anderson departs as pharma CEO. Mon, 12/12/2022 - 09:25.

Pharma

Fierce Pharma Asia—BioNTech, GSK grow in Singapore; Astellas' stomach cancer win; Daiichi's mRNA vaccine readout

Fierce Pharma

NOVEMBER 18, 2022

Fierce Pharma Asia—BioNTech, GSK grow in Singapore; Astellas' stomach cancer win; Daiichi's mRNA vaccine readout. Fri, 11/18/2022 - 09:44.

Pharma

Leo Pharma scores with its JAK inhibitor cream in chronic hand eczema trial

Fierce Pharma

DECEMBER 6, 2022

Leo Pharma scores with its JAK inhibitor cream in chronic hand eczema trial. Tue, 12/06/2022 - 10:04.

Pharma

Eli Lilly CEO racked up $21.4M in 2022 pay as stock price hit all-time high

Fierce Pharma

MARCH 20, 2023

in 2022 pay as stock price hit all-time high aliu Mon, 03/20/2023 - 10:51 Eli Lilly CEO racked up $21.4M

Coming and going paid off for biopharma CEOs in 2022

Fierce Pharma

JUNE 26, 2023

There was a decline in CEO compensation overall in 2022. But there was no evidence of the slide in biopharma where pay increases were plentiful.

Biopharma

Fierce Pharma Asia—Eisai's lecanemab Alzheimer's debate; BeiGene's Imbruvica showdown; Shionogi's COVID drug nod

Fierce Pharma

DECEMBER 2, 2022

Fierce Pharma Asia—Eisai's lecanemab Alzheimer's debate; BeiGene's Imbruvica showdown; Shionogi's COVID drug nod. Fri, 12/02/2022 - 08:55.

Pharma

Is pharma being unfairly targeted by the media?

World of DTC Marketing

MARCH 8, 2022

It’s hard to justify those price increases, but pharma is big business, as all parties in healthcare are. Many people I talk with acknowledge that pharma has been profiteering from drug sales, but they balance that with the need for new drugs to help patients live a better quality of life. million people have died.

Media

Media Pharma Insurance Prescription

Roche trial confirms Vabysmo efficacy in minorities

pharmaphorum

OCTOBER 21, 2024

billion in the first half of the year.

Sales

Sales FDA Pharma Patients

Divya Iyer, VP Strategy & Business Development at GoodRx, showcases digital health innovations at Digital Pharma East conference

Fierce Pharma

NOVEMBER 10, 2022

Divya Iyer, VP Strategy & Business Development at GoodRx, showcases digital health innovations at Digital Pharma East conference. Thu, 11/10/2022 - 13:14.

Pharma

After 2022's M&A spree, Amgen CEO Bradway collects $21.4M payday

Fierce Pharma

APRIL 7, 2023

After 2022's M&A spree, Amgen CEO Bradway collects $21.4M payday zbecker Fri, 04/07/2023 - 12:10

Roche's star eye drug Vabysmo crosses blockbuster threshold as rival stalls at FDA

Fierce Pharma

JULY 27, 2023

To Roche’s pharma chief Teresa Graham, no word better describes the company’s eye drug Vabysmo right now than “momentum.” | To Roche’s pharma chief Teresa Graham, no word better describes the company’s eye drug Vabysmo right now than “momentum.”

FDA

FDA Pharma Sales

AstraZeneca withdraws US COVID vaccine application, shifts focus to antibody treatments

Fierce Pharma

NOVEMBER 10, 2022

Thu, 11/10/2022 - 09:02. AstraZeneca withdraws US COVID vaccine application, shifts focus to antibody treatments.

With $1.2B stock sale, GSK offloads more of its stake in consumer health spinoff Haleon

Fierce Pharma

JANUARY 17, 2024

GSK is sticking to its plan to gradually monetize its stake in Haleon, the consumer health business the British pharma giant spun off in 2022. | GSK is sticking to its plan to gradually monetize its stake in Haleon, the consumer health business the British pharma giant spun off in 2022.

Sales

Sales Pharma

Pharma running online ads on vaccine misinformation sites

World of DTC Marketing

FEBRUARY 19, 2021

When will pharma stop using programmatic online ads? Again and again, I have seen robust fraud and online ads being placed on sites that pharma would normally block in their system. If pharma is going to waste money like this perhaps they could send the money to those who need it. dollars in 2018.

Pharma

Pharma Media Leads Marketing

Pfizer, Sanofi settle first California Zantac case slated for trial: report

Fierce Pharma

DECEMBER 22, 2022

Thu, 12/22/2022 - 12:38. Pfizer, Sanofi settle first California Zantac case slated for trial: report.

Amgen, J&J and Sanofi size up Horizon as Big Pharma renews interest in rare disease M&A

Fierce Pharma

NOVEMBER 29, 2022

Amgen, J&J and Sanofi size up Horizon as Big Pharma renews interest in rare disease M&A. Wed, 11/30/2022 - 00:16.

Pharma

Bavarian Nordic scores $157M contract to replenish US supplies of smallpox/mpox vaccine Jynneos

Fierce Pharma

AUGUST 8, 2024

million to “partly replenish” Jynneos vaccine stocks in response to the 2022 outbreak of mpox, the disease formerly known as monkeypox. . | The Biomedical Advanced Research and Development Authority (BARDA) is handing Bavarian Nordic $156.8

Government

High-flying Vertex hikes CEO Reshma Kewalramani's pay by 30% to $20.6M

Fierce Pharma

APRIL 5, 2024

million pay in 2022. Vertex CEO Reshma Kewalramani, M.D., million in 2023, which was an increase of 30% from her $15.9

Moderna’s Spikevax carries higher risk of myocarditis than Pfizer's Comirnaty, study says

Fierce Pharma

NOVEMBER 8, 2022

Tue, 11/08/2022 - 11:03. Moderna’s Spikevax carries higher risk of myocarditis than Pfizer's Comirnaty, study says.

With Pfizer struggling in 2023, CEO Bourla hit with 35% pay cut to $21.6M

Fierce Pharma

MARCH 15, 2024

After a difficult year for Pfizer, in which its share price fell by 44%, CEO Albert Bourla’s compensation fell by 35% from $33 million in 2022 to $21.6 But even the drugmaker was surprised by the plummeting demand for its COVID-19 products, missing badly on its 2023 guidance. million in 2023.

Atara makes history with world-first nod for allogeneic T-cell therapy Ebvallo

Fierce Pharma

DECEMBER 19, 2022

Mon, 12/19/2022 - 14:06. Atara makes history with world-first nod for allogeneic T-cell therapy Ebvallo. fkansteiner.

Biogen, FDA's inappropriate Aduhelm coordination detailed in blistering congressional report

Fierce Pharma

DECEMBER 29, 2022

Thu, 12/29/2022 - 14:42. Biogen, FDA's inappropriate Aduhelm coordination detailed in blistering congressional report. aarmstrong.

FDA

Arcutis' Zoryve bags 2nd FDA nod, this time as a foam to treat 'the great neglected disease in dermatology'

Fierce Pharma

DECEMBER 15, 2023

About a year after Arcutis Biotherapeutics unveiled positive data on roflumilast foam at the European Academy of Dermatology and Venereology congress 2022, the company has clinched a second FDA OK.

FDA

Novartis Returns to Voyager Therapeutics to Reach New Gene Therapy Destinations

MedCity News

JANUARY 2, 2024

The deal builds on a relationship the companies started in 2022. Novartis is paying Voyager Therapeutics $100 million up front to collaborate on gene therapies for Huntington’s disease and spinal muscular atrophy.

Biopharma

Biopharma Pharma

Despite pharma growth, Merck KGaA's CDMO slowdown plays into company's overall sales decline

Fierce Pharma

MARCH 7, 2024

After posting revenue increases for six straight years, including double-digit growth in 2021 and 2022, Merck KGaA took a hard fall last year, with its global sales

Sales

Sales Pharma

Akero’s New MASH Drug Data: Longer Treatment Leads to More Liver Benefit

MedCity News

MARCH 4, 2024

The latest Akero data build on six-month results reported in 2022. Akero Therapeutics’ preliminary Phase 2b data show that treatment with its MASH drug, efruxifermin, continued to distance itself from a placebo measured at nearly two years of treatment.

Leads

Leads Biopharma Pharma

Cancer center leaders lay bare CAR-T makers' struggles—and an unexpected laggard

Fierce Pharma

DECEMBER 13, 2022

Tue, 12/13/2022 - 20:12. Cancer center leaders lay bare CAR-T makers' struggles—and an unexpected laggard.

Sporting a $3.5M price tag, CSL and uniQure's hemophilia B gene therapy crosses FDA finish line

Fierce Pharma

NOVEMBER 23, 2022

Wed, 11/23/2022 - 10:10. Sporting a $3.5M price tag, CSL and uniQure's hemophilia B gene therapy crosses FDA finish line.

FDA

Gilead’s $285M Confidence Vote for Next-Gen Cancer Med & New Cell Therapy Tech

MedCity News

NOVEMBER 15, 2023

Gilead Sciences is increasing its stake in partner Arcellx and expanding the cell therapy alliance the companies started in 2022. The deal expands the lead partnered program to more cancers and gives Gilead a chance at another Arcellx cell therapy candidate made with different technology.

Leads

Leads Biopharma Pharma

Watch out, Amgen. Mirati kicks off KRAS showdown with FDA approval for Krazati

Fierce Pharma

DECEMBER 12, 2022

Mon, 12/12/2022 - 18:14. Watch out, Amgen. Mirati kicks off KRAS showdown with FDA approval for Krazati.

FDA

Genentech starts phase 2 trial to optimize delivery of eye disease cell therapy

Fierce Pharma

NOVEMBER 28, 2022

Mon, 11/28/2022 - 10:11. Genentech starts phase 2 trial to optimize delivery of eye disease cell therapy.

Editor's corner: Fierce Pharma's top 10 stories of 2022

Roche Expands Its Scope in Allogeneic Cell Therapy With $1B Poseida Therapeutics Acquisition

Trending Sources

Drug Approvals in 2022: A Recap of Notable FDA Regulatory Decisions

Bristol Myers Squibb’s Sotyktu Meets Goals in Two Pivotal Psoriatic Arthritis Studies

A realistic view of healthcare in 2022

10 noteworthy pharma leadership shake-ups this year

Activist shareholders ask 9 big pharmas to consider whether 'excessive' patenting hurts access

Pharma Injecting Life into Digital Health Amidst Funding Downturn

2023 forecast: FDA revamps cancer drug approvals, and Big Pharma is willing to fall in line

How pharma marketing must adapt to patient personalization

Thea Pharma gets FDA nod for preservative-free rival to Sun and Viatris glaucoma eye drops

AbbVie CEO Gonzalez scored $26M in 2022 pay as cash cow Humira neared patent cliff

Cancer Biotech Repare Therapeutics Restructures to Focus on Clinical-Stage Pipeline

In another leadership change at Roche, Anderson departs as pharma CEO

Fierce Pharma Asia—BioNTech, GSK grow in Singapore; Astellas' stomach cancer win; Daiichi's mRNA vaccine readout

Leo Pharma scores with its JAK inhibitor cream in chronic hand eczema trial

Eli Lilly CEO racked up $21.4M in 2022 pay as stock price hit all-time high

Coming and going paid off for biopharma CEOs in 2022

Fierce Pharma Asia—Eisai's lecanemab Alzheimer's debate; BeiGene's Imbruvica showdown; Shionogi's COVID drug nod

Is pharma being unfairly targeted by the media?

Roche trial confirms Vabysmo efficacy in minorities

Divya Iyer, VP Strategy & Business Development at GoodRx, showcases digital health innovations at Digital Pharma East conference

After 2022's M&A spree, Amgen CEO Bradway collects $21.4M payday

Roche's star eye drug Vabysmo crosses blockbuster threshold as rival stalls at FDA

AstraZeneca withdraws US COVID vaccine application, shifts focus to antibody treatments

With $1.2B stock sale, GSK offloads more of its stake in consumer health spinoff Haleon

Pharma running online ads on vaccine misinformation sites

Pfizer, Sanofi settle first California Zantac case slated for trial: report

Amgen, J&J and Sanofi size up Horizon as Big Pharma renews interest in rare disease M&A

Bavarian Nordic scores $157M contract to replenish US supplies of smallpox/mpox vaccine Jynneos

High-flying Vertex hikes CEO Reshma Kewalramani's pay by 30% to $20.6M

Moderna’s Spikevax carries higher risk of myocarditis than Pfizer's Comirnaty, study says

With Pfizer struggling in 2023, CEO Bourla hit with 35% pay cut to $21.6M

Atara makes history with world-first nod for allogeneic T-cell therapy Ebvallo

Biogen, FDA's inappropriate Aduhelm coordination detailed in blistering congressional report

Arcutis' Zoryve bags 2nd FDA nod, this time as a foam to treat 'the great neglected disease in dermatology'

Novartis Returns to Voyager Therapeutics to Reach New Gene Therapy Destinations

Despite pharma growth, Merck KGaA's CDMO slowdown plays into company's overall sales decline

Akero’s New MASH Drug Data: Longer Treatment Leads to More Liver Benefit

Cancer center leaders lay bare CAR-T makers' struggles—and an unexpected laggard

Sporting a $3.5M price tag, CSL and uniQure's hemophilia B gene therapy crosses FDA finish line

Gilead’s $285M Confidence Vote for Next-Gen Cancer Med & New Cell Therapy Tech

Watch out, Amgen. Mirati kicks off KRAS showdown with FDA approval for Krazati

Genentech starts phase 2 trial to optimize delivery of eye disease cell therapy

Stay Connected